Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.

I call it my AI Retirement Playbook. I recommend you check it out now.

Timothy A. Springer net worth and biography

Timothy Springer Biography and Net Worth

Director of Morphic

Timothy Springer, PhD, Founder, Morphic Therapeutic is Latham Family Professor at Harvard Medical School and Professor of Medicine at Children’s Hospital Boston.

Tim Springer, Ph.D. – an immunologist and biophysicist serving as Latham Family Professor at Harvard Medical School and Boston Children’s Hospital – discovered integrins and their ligands in the 1980s and since then, has worked on elucidating regulation of their biological function. His pioneering work resulted in the detailed characterization of integrin structure and robust understanding of biophysical phenomena underlying their activation. This has led to the founding of multiple biotechnology companies (LeukoSite , Scholar Rock, Morphic Therapeutic) and approved therapeutics including Amevive®, Raptiva®, Campath®, Velcade®, and Entyvio®). Morphic Therapeutics Inc., capitalizes on his 15 years of study of the molecular mode of action underlying unproductive interactions between small-molecule drugs and their integrin targets in the disease tissue. These findings make possible small molecule antagonists which reverse their activation by preventing them from occupying disease-specific signaling and conformational states. Tim is a member of Morphic Board of Directors and Scientific Advisory Board and provides strategic guidance to all research and development activities of Morphic Therapeutic.

What is Timothy A. Springer's net worth?: The estimated net worth of Timothy A. Springer is at least $233.47 million as of October 22nd, 2024. Dr. Springer owns 4,096,764 shares of Morphic stock worth more than $233,474,580 as of December 25th. This net worth approximation does not reflect any other investments that Dr. Springer may own. Additionally, Dr. Springer receives a salary of $40,000.00 as Director at Morphic. Learn More about Timothy A. Springer's net worth.
How old is Timothy A. Springer?: Dr. Springer is currently 76 years old. There are 6 older executives and no younger executives at Morphic. Learn More on Timothy A. Springer's age.
What is Timothy A. Springer's salary?: As the Director of Morphic Holding, Inc., Dr. Springer earns $40,000.00 per year. There are 4 executives that earn more than Dr. Springer. The highest earning executive at Morphic is Dr. Praveen P. Tipirneni M.D., CEO, MD & Director, who commands a salary of $991,330.00 per year. Learn More on Timothy A. Springer's salary.
How do I contact Timothy A. Springer?: The corporate mailing address for Dr. Springer and other Morphic executives is 35 Gatehouse Drive A2, Waltham MA, 02451. Morphic can also be reached via phone at (781) 996-0955. Learn More on Timothy A. Springer's contact information.
Has Timothy A. Springer been buying or selling shares of Morphic?: Timothy A. Springer has not been actively trading shares of Morphic during the past quarter. Most recently, on Wednesday, May 3rd, Timothy A. Springer bought 1,050,000 shares of Morphic stock. The stock was acquired at an average cost of $45.00 per share, with a total value of $47,250,000.00. Following the completion of the transaction, the director now directly owns 2,768,464 shares of the company's stock, valued at $124,580,880. Learn More on Timothy A. Springer's trading history.
Who are Morphic's active insiders?: Morphic's insider roster includes Robert Farrell, Jr. (CAO), Peter Linde (Insider), Bruce Rogers (Insider), Marc Schegerin (CFO), and Timothy Springer (Director). Learn More on Morphic's active insiders.
Are insiders buying or selling shares of Morphic?: During the last twelve months, insiders at the sold shares 10 times. They sold a total of 161,666 shares worth more than $8,004,797.42. The most recent insider tranaction occured on July, 8th when President Bruce Rogers sold 20,000 shares worth more than $1,115,800.00. Insiders at Morphic own 25.6% of the company. Learn More about insider trades at Morphic.
Information on this page was last updated on 7/8/2024.

Timothy A. Springer Insider Trading History at Morphic

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/3/2023	Buy	1,050,000	$45.00	$47,250,000.00	2,768,464
8/20/2021	Buy	11,620	$56.79	$659,899.80
8/18/2021	Buy	30,307	$55.70	$1,688,099.90
5/26/2021	Buy	25,000	$46.97	$1,174,250.00	4,565,191
5/24/2021	Buy	40,000	$46.51	$1,860,400.00	4,565,191
3/5/2021	Buy	100,000	$70.00	$7,000,000.00	4,565,191
7/1/2019	Buy	33,333	$15.00	$499,995.00

Timothy A. Springer Buying and Selling Activity at Morphic

Morphic Company Overview

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $56.99

$56.99

50 Day Range

MA: $56.76

$55.74

$56.99

2 Week Range

Now: $56.99

$19.34

$57.00

Volume

400 shs

Average Volume

1,272,131 shs

Market Capitalization

$2.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.49

Most People Are Dead Wrong.

From Brownstone Research | Ad

I call it my AI Retirement Playbook. I recommend you check it out now.

Timothy Springer Biography and Net Worth

What is Timothy A. Springer's net worth?

How old is Timothy A. Springer?

What is Timothy A. Springer's salary?

How do I contact Timothy A. Springer?

Has Timothy A. Springer been buying or selling shares of Morphic?

Who are Morphic's active insiders?

Are insiders buying or selling shares of Morphic?